



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of)

Eliezer MASLIAH)

Serial No.: 09/933,640)

Filed: August 20, 2001)

FOR: DEVELOPMENT TO
TRANSGENIC MODEL FOR
INTERVENTIONS IN
NEURODEGENERATIVE
DISEASES

Group
Art Unit: 1632

RECEIVED

AUG 13 2002

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents
P. O. Box 2327
Arlington, VA 22202

Attention: Examiner

Dear Sir:

Applicants submit herewith references of which they are aware, which they believe may be material to patentability of the invention disclosed and claimed in the above-cited application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

August 6, 2002

(Mailing Date)

Karen Johnson

(Typed Name)

Karen Johnson
(Signature)

August 6, 2002

(Date of Signature)

Applicants are submitting herewith copies of the references which are set forth on the attached Form PTO/SB/08A. As all relevant parts of the references are in the English language, no explanation of the references is provided herein.


This Information Disclosure Statement is submitted within three (3) months of the filing date of the above-cited application or of the date of entry into the national phase of the application or prior to the mailing date of a first Office Action thereon, whichever has occurred last, such that no fee is required.

Further, while the references provided in this Information Disclosure Statement may be material to patentability pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specifically designated as such.

Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists.

Respectfully submitted,

Dated: August 6, 2002

By: 
Colleen J. McKiernan
Patent Agent for Applicants
Registration No. 48,570

BROWN MARTIN HALLER & McCLAIN LLP
1660 Union Street
San Diego, California 92101

Telephone: (619) 238-0999
Facsimile: (619) 238-0062

Docket No.: 6627-PA1071



1632
#5
Dec
8/13/02

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/933,640	
	Filing Date	August 20, 2001	
	First Named Inventor	Eliezer MASLIAH et al.	
	Group Art Unit	1632	
	Examiner Name	UNKNOWN	
Total Number of Pages in This Submission	8	Attorney Docket Number	6627-PA1071

RECEIVED
AUG 13 2002


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): Form SB/08A; cited references; return postcard
<input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)		
<input type="checkbox"/> Extension of Time Request		
<input type="checkbox"/> Express Abandonment Request		
<input checked="" type="checkbox"/> Information Disclosure Statement		
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Colleen J. McKiernan 48,570
Signature	
Date	August 6, 2002

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the U. S. Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202 on this date: 08/06/2002	
Typed or printed name	Karen Johnson
Signature	
Date	August 6, 2002


Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED
AUG 19 1962
TECH CENTER 1600/2901
Division of

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number		
				Filing Date		
				First Named Inventor		
				Group Art Unit		
				Examiner Name		
Sheet		2	of	5	Attorney Docket Number	6627-PA1071
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
	1	Andrää, K., Abramowski, D., Duke, M., Probst, A., Wiederhold, K.-H., Bührki, K., Goedert, M., Sommer, B. & Staufenbiel, M. (1996) Expression of APP in transgenic mice: a comparison of neuron-specific promoters. <i>Neurobiol. Aging</i> 17, 183-190.				
	2	Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, Price DL. (1996) A vector for expressing foreign genes in the brains and hearts of transgenic mice. <i>Genet. Anal.</i> 13:159-63.				
	3	Carlson, G.A., Borchelt, D.R., Dake, A., Turner, S., Danielson, V., Coffin, J.D., Eckman, C., Meiners, J., Nilsen, S.P., Younkin, S.G. and Hsiao (1997) Genetic modification of phenotypes produced by amyloid precursor protein overexpression in transgenic mice. <i>Hum. Mol. Gen.</i> 6:1951-9.				
	4	Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., <i>et al.</i> (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. <i>Nature (London)</i> 373, 523-528.				
	5	Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., Trojanowski, J.Q., Lee, V.M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. <i>Science</i> 290:985-9.				
	6	Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M. and Masliah, E. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/ α -synuclein <i>in vitro</i> . <i>Neuroreport</i> 10:717-21.				
	7	Higgins, L. S., Rodems, J. M., Catalano, R., Quon, D. & Cordell, B. (1995) Early Alzheimer's disease-like histopathology increases in frequency with age in mice transgenic for β -APP751. <i>Proc. Natl. Acad. Sci. USA</i> 92, 4402-4406.				
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

AUG 13 2002




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/933,640
				Filing Date	August 20, 2001
				First Named Inventor	Eliezer MASLIAH
				Group Art Unit	1632
				Examiner Name	Unknown
Sheet	3	of	5	Attorney Docket Number	6627-PA1071
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	8	Holtzman, D.M., Bales, K.R., Tenkova, T., Fagan, A.M., Parsadarian, M., Sartorius, L.J., Mackey, B.M., Olney, J., McKeel, D., Wozniak, D. and Paul, S.M. (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degradation in a mouse model of Alzheimer's disease. <i>Proc. Natl. Acad. Sci.</i> 97:2892-7.			
	9	Hsia, A.Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R.C., Nicoll, R.A. and Mucke, L. (1999) Plaque independent disruption of neural circuits in Alzheimer's disease mouse models. <i>Proc Natl. Acad. Sci. USA</i> 96:3228-33.			
	10	Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin S, Price D, et al.(1995) Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. <i>Neuron</i> 15:1203-18			
	11	Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. & Cole, G. (1996) Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice. <i>Science</i> 274: 99-102			
	12	Kammesheidt, A., Boyce, F. M., Spanoyannis, A. F., Cummings, B. J., Ortegon, M., Cotman, C., Vaught, J. L. & Neve, R. L. (1992) Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. <i>Proc. Natl. Acad. Sci. USA</i> 89, 10857-10861.			
	13	Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B. (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. <i>Nature</i> 325:733-6.			
	14	Lamb, B. T., Sisodia, S. S., Lawler, A. M., Slunt, H. H., Kitt, C. A., Kearns, W. G., Pearson, P. L., Price, D. L. & Gearhart, J. D. (1993) Introduction and expression of the 400 kilobase amyloid precursor protein gene in transgenic mice <i>Nat. Genet.</i> 5, 22-30.			
Examiner Signature					Date Considered

RECEIVED
AUG 13 2002
TECH CENTER 1600/2900

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/933,640
				Filing Date	August 20, 2001
				First Named Inventor	Eliezer MASLIAH
				Group Art Unit	1632
				Examiner Name	Unknown
Sheet	4	of	5	Attorney Docket Number	6627-PA1071
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	15	Masliah, E., Rockenstein, E.M., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., Mucke, L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. <i>Science</i> 287:1265-9.			
	16	Morris R. (1984) Developments of a water-maze procedure for studying spatial learning in the rat. <i>J. Neurosci. Meth.</i> 11:47-60.			
	17	Mucke, L., Masliah, E., Johnson, W. B., Ruppe, M. D., Alford, M., Rockenstein, E. M., Forss-Petter, S., Pietropaolo, M., Mallory, M. & Abraham, C. R. (1994) Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice <i>Brain Res.</i> 666, 151-167.			
	18	Mucke, L., Abraham, C.R., Ruppe, M.D., Rockenstein, E. M., Toggas, S.M., Mallory, M., Alford, M. and Masliah, E. (1995) Protection against HIV-1 gp120-induced brain damage by neuronal overexpression of human amyloid precursor protein (hAPP) <i>J.Exp.Med.</i> 181: 1551-56.			
	19	Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E.M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K. and McConlogue, L. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation <i>J. Neurosci.</i> 20:4050-8.			
	20	Quon, D., Wang, Y., Catalano, R., Scardina, J. M., Murakami, K. & Cordell, B. (1991) Formation of beta-amyloid protein deposits in brains of transgenic mice <i>Nature (London)</i> 352:239-241.			
	21	Rockenstein EM, McConlogue L, Tan H, Power M, Masliah E, Mucke L (1995) Levels and alternative splicing of amyloid beta protein precursor (APP) transcripts in brains of APP transgenic mice and humans with Alzheimer's disease. <i>J. Biol. Chem.</i> 270:28257-28267.			
Examiner Signature					Date Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

TECH CENTER 1600/2900

AUG 13 2002



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

(use as many sheets as necessary)

Complete if Known

Application Number	09/933,640
--------------------	------------

Filing Date	August 20, 2001
-------------	-----------------

First Named Inventor	Eliezer MASLIAH
----------------------	-----------------

Group Art Unit	1632
----------------	------

Examiner Name	UNKNOWN
---------------	---------

Sheet	5	of	5	Attorney Docket Number	6627-PA1071
-------	---	----	---	------------------------	-------------

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.